Terns Pharmaceuticals’ decision to drop its liver disease ambitions may yet pay off, after the biotech posted phase 1 data ...

Eyeing the success of GLP-1s are Chinese biopharmaceutical companies pushing semaglutide biosimilars and GLP-1 therapy candidates up the pipeline. And the crowding market is pushing the innovators to ...

Fatty liver disease linked to diabetes and obesity can easily progress to liver cirrhosis, but new research suggests that GLP ...

Novo Nordisk A/S's shares have stalled recently, but this looks like a natural digestion of gains from prior years. Click for ...

Terns Pharmaceuticals will advance TERN-601 into Phase II after early-stage data showed the oral therapy led to weight loss ...

Why fork over thousands of dollars a month for prescription weight loss jabs when store-bought supplements claim to have the ...

Eli Lilly and Company’s LLY stock has risen 21.1% in six months compared with an increase of 10.5% for the industry. The ...

Discover Citi's bullish outlook on Eli Lilly with a $1,060 target. Is now the time to invest? Find key insights and price ...

Whether positive or negative, your mood may feel different on GLP-1 medications. Researchers share why that might be and how ...

Charting, Price Performance, News & Related Contracts.

Novo Nordisk reported that its new obesity pill led to substantial weight loss in an early study, boosting the company’s ...

Here's what doctors think about them. Weight loss with Ozempic or Wegovy can be effective, but expensive. Enter so-called GLP-1 supplements that have taken on the nickname “nature’s Ozempic.” They’re ...